TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019.

ABSTRACT: Liver fibrosis is an advanced liver disease condition, which could progress to cirrhosis and hepatocellular carcinoma. To date, there is no direct approved antifibrotic therapy, and current treatment is mainly the removal of the causative factor. Transforming growth factor (TGF)-β is a master profibrogenic cytokine and a promising target to treat fibrosis. However, TGF-β has broad biological functions and its inhibition induces non-desirable side effects, which override therapeutic benefits. Therefore, understanding the pleiotropic effects of TGF-β and its upstream and downstream regulatory mechanisms will help to design better TGF-β based therapeutics. Here, we summarize recent discoveries and milestones on the TGF-β signaling pathway related to liver fibrosis and hepatic stellate cell (H

SUBMITTER: Dewidar B 

PROVIDER: S-EPMC6912224 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature